While still in the early stages of development, in vivo CAR-T therapies have generated excitement about their potential as cancer therapies, and updates from a couple of class pioneers at ASCO will ...

As it waits for an FDA decision on one non-opioid pain drug, Viatris has its eye on two more, via a takeover bid for Pacira ...

The steady stream of M&A deals in pharma this year has continued with the news that GSK has agreed to buy Canada's 35Pharma and its drug candidate for pulmonary hypertension (PH) for $950 million. The ...

Sanofi's long-running R&D alliance with Regeneron has gone up a gear with a partnership – worth up to $8 billion – that spans ...

AstraZeneca's pivot towards the US market has continued with the opening of a new R&D centre in the biotech hotspot of ...

Just months after launching an open-source 'virtual biology' platform, non-profit research organisation Biohub has raised ...

US pharma trade organisation PhRMA is challenging the Trump administration's GLOBE model for Most-Favoured Nation (MFN) ...

MSD has been rocked by a court judgment ordering it to stop manufacturing and selling its subcutaneous formulation of cancer ...

Exclusive analysis for World Health Expo (WHX) by Frost & Sullivan forecasts precision medicine growth of more than 10% in ...

Pfizer acquired Tukysa as part of its $43 billion takeover of Seagen in 2023, three years after the drug first reached the US ...

Raising funding, assembling the initial team, building lab operations from the ground up, generating proof-of-concept ...

AZ's $2 billion investment – at $18.36 per share – puts the UK-headquartered company in the driving seat to pair its ...